This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Osteoarthritis  • Randomized Controlled Trial  • Rheumatoid Arthritis  • Drug Therapy, Other  • Immunologic Disorders  • Alert me on articles by topic

Tracy Hampton, PhD

JAMA. 2007;297:28-29.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Washington, DC—Late-breaking research presented at the recent annual conference of the American College of Rheumatology and the Association of Rheumatology Health Professionals highlighted results from phase 2 and 3 clinical trials testing experimental agents to treat arthritis. Candidates ranged from the nonspecific anti-inflammatory chondroitin sulfate to biologic agents that target specific immune response modifiers.

RHEUMATOID ARTHRITIS AGENTS

For rheumatoid arthritis, a disease characterized by immune and/or inflammatory responses gone awry, researchers are testing the potential of a number of therapies that target immune response modifiers, such as cytokines and their cell receptors. An international team of investigators reported results from a randomized, double-blind, placebo-controlled phase 2a trial of a drug called CP-690,550, which inhibits a receptor for several interleukins and had shown efficacy in targeting this receptor (Janus kinase 3) in rodent models of arthritis and in humans with psoriasis.

A variety of experimental agents have completed phase 2 . . . [Full Text of this Article]